StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Prazosin

HCID 4893
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
19216-56-9
Standard-SMILES
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
Summenformel
C19H21N5O4
Durchschnittliche Molmasse
383,4 g/mol
Monoisotopische Masse
383,15935417

Überblick

Prazosin is a member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a member of furans, a member of piperazines, a monocarboxylic acid amide, an aromatic ether and a member of quinazolines.

Namen und Bezeichner

Bevorzugter Name
Prazosin
IUPAC
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
Lokaler Name
Prazosin
Englischer Name
Prazosin
Summenformel
C19H21N5O4
Molmasse
383.4

Namen und Synonyme

prazosin19216-56-9FurazosinPrazosinePrazosinaPrazosinum1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazolineDTXSID4049082Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-XM03YJ541DCP-122991
Weitere Namen anzeigen
pressinminipressAKOS B020009PrazosinBaseTerazosin-010Prazosin USP/EP/BPART-CHEM-BB B020009
CHEBI:8364DTXCID0029008Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine2-[4-(2-Furoyl)piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)-furan-2-ylmethanone[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-furan-2-ylmethanone2-(4-((furan-2-yl)carbonyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2
Polarare Oberfläche (TPSA)
107 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
4
Schwere Atome
28
Formalladung
0
Komplexität
544

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 Einträge

1.3

1.9

Solubility6.93e-01 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Adrenergic alpha-Antagonists; Antihypertensive Agents

Pharmaceuticals

Melting Point · 2 Einträge

277-280

279 °C

Physical DescriptionSolid
Dissociation Constants6.54
Collision Cross Section · 2 Einträge

192.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

186.41 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Other Safety InformationIMAP assessments - Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (50%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Prazosin has been associated with a low rate of serum aminotransferase elevations that in controlled trials was no higher than with placebo therapy. These elevations were transient and did not require dose modification. No instances of clinically apparent acute liver injury due to prazosin have been published in the literature, but reports of cholestatic hepatitis have been received by the sponsor. Among the alpha adrenergic receptor antagonists, the most frequently implicated agent in causing liver injury has been alfuzosin with only single, and not well documented cases linked to other alpha blockers. Thus, acute symptomatic liver injury due to prazosin is quite rare, and severe hepatotoxicity must be exceeding rare, if it occurs at all.

Adverse Effects

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

C02CA01

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingHighly bound to proteins with 97% binding to albumin and alpha 1-acid glycoprotein. Prazosin is thought to be mostly (about 80-90%) bound to albumin.
Pharmacodynamics · 1 Eintrag

**Effects on blood pressure** The pharmacodynamic and therapeutic effect of this drug includes is a decrease in blood pressure as well as clinically significant decreases in cardiac output, heart rate, blood flow to the kidney, and glomerular filtration rate. The decrease in blood pressure may occur in both standing and supine positions. Many of the above effects are due to vasodilation of blood vessels caused by prazosin, resulting in decreased peripheral resistance,. Peripheral resistance refers to the level resistance of the blood vessels to blood that flows through them. As the blood vessels constrict (narrow), the resistance increases and as they dilate (widen), and peripheral resistance decreases, lowering blood pressure. **Effects on sleep disturbance related to post-traumatic stress disorder (PTSD)** Some studies have suggested that this drug improves sleep in patients suffering from insomnia related to nightmares and post-traumatic stress disorder, caused by hyperarousal. This effect likely occurs through the inhibition of adrenergic stimulation found in states of hyperarousal.

Mechanism of Action · 1 Eintrag

Alpha-adrenergic receptors are essential for the regulation of blood pressure in humans. Two types of alpha receptors, alpha 1 and alpha 2, both play a role in regulating blood pressure. Alpha-1 receptors are postsynaptic (located after the nerve junction, or space between a nerve fiber and target tissue). In this case, the target tissue is the vascular smooth muscle. These receptors, when activated, increase blood pressure. Prazosin inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting (narrowing) effect of catecholamines (epinephrine and norepinephrine) on the vessels, leading to peripheral blood vessel dilation. Through blood vessel constriction by adrenergic receptor activation, epinephrine and norepinephrine normally act to increase blood pressure.

Zugehörige Reaktionen

10
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 372680
HRID 372680als Produkt
Reaktionsgleichung von HRID 461331
HRID 461331als Produkt
Reaktionsgleichung von HRID 461336
HRID 461336als Produkt
Reaktionsgleichung von HRID 826660
HRID 826660als Produkt
Reaktionsgleichung von HRID 840093
HRID 840093als Produkt
Reaktionsgleichung von HRID 979728
HRID 979728als Edukt
Reaktionsgleichung von HRID 1576327
HRID 1576327als Produkt
Reaktionsgleichung von HRID 1580969
HRID 1580969als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
19216-56-9
PubChem CID
4893
DTXSID
DTXSID4049082
ChEMBL
CHEMBL2
ChEBI
CHEBI:8364
UNII
XM03YJ541D
EC Number
242-885-8
Nikkaji
J10.000E

Physikochemische Eigenschaften

Schmelzpunkt
278 · 278-280°C
Siedepunkt
510.33 °C · 510.33°C (rough estimate)
Dichte
1.3275 · 1.3275 (rough estimate)
Brechungsindex
1.76 · 1.7600 (estimate)
storage temp.
2 · 2-8°C
Löslichkeit
DMSO (Slightly), Methanol (Slightly, Heated)
Aggregatzustand
Solid
pka
6.54 · pKa 6.54(50% EtOH) (Uncertain)
Farbe
White to Off-White
Wasserlöslichkeit
3.2 mg/L · 3.2mg/L(22.5 ºC)
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
SMILES
C(N1CCN(C2=NC(N)=C3C(=N2)C=C(OC)C(OC)=C3)CC1)(C1=CC=CO1)=O
Serious Adverse Effects
Toxicity SummaryThere is no direct toxicity with this medication. High doses and overdoses could lead to hypotension, and patients should be supported clinically with volume resuscitation if necessary or pressor support.
Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

prazosin

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315
Biological Half-LifeThe plasma half-life is about 2-3 hours.
Metabolism/MetabolitesIn animals, prazosin hydrochloride is heavily metabolized. This occurs through liver demethylation and conjugation. Some studies in humans or human cells in vitro show similar prazosin metabolism.
FDA Pharmacological Classification · 6 Einträge

XM03YJ541D

PRAZOSIN

Mechanisms of Action [MoA] - Adrenergic alpha-Antagonists

Established Pharmacologic Class [EPC] - alpha-Adrenergic Blocker

Prazosin is an alpha-Adrenergic Blocker. The mechanism of action of prazosin is as an Adrenergic alpha-Antagonist.

PRAZOSIN

MeSH Pharmacological Classification · 2 Einträge

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Absorption, Distribution and Excretion · 4 Einträge

After administration of an oral dose, peak plasma concentrations are attained at approximately 3 hours. There is a linear association between the prazosin dose given and plasma concentration at steady state.

This drug is mainly excreted in the bile and the feces.

About 0.6 L/kg.

In patients with congestive heart failure, the clearance of this drug is decreased. Impairment of renal function does not have relevant effects on elimination.

Cellular LocationsExtracellular

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >10
Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

HistoryPrazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.According to FDA, in October 2025, New Jersey-based drugmaker Teva Pharmaceuticals USA and drug distributor Amerisource Health Services issued voluntary nationwide recalls of over half a million bottles of various strengths of prazosine capsules, which may include a cancer-causing chemical.

VerwendenPrazosin is used for treating mid-to-moderate hypertension. When using this drug, blood pressure is reduced without any significant change in indicators of cardiac function such as frequency, coronary flow, or cardiac output.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

1-(2-Furoyl)piperazinBenzonitrilAmmonia-ammonium chlorideMethyljodidThioharnstoffAmmoniak, wasserfrei2-Furoylchlorid2-Chlor-6,7-dimethoxychinazolin-4-aminPiperazin2,4-Dichloro-6,7-dihydro-5H-cyclopentapyrimidine

Nachgelagerte Produkte

Bunazosin

Ergänzende Hinweise

DefinitionChEBI: A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.